zimberelimab   Click here for help

GtoPdb Ligand ID: 12349

Synonyms: AB-122 | AB122 | GLS-010
Approved drug Immunopharmacology Ligand
zimberelimab is an approved drug (China (2021))
Compound class: Antibody
Comment: Zimberelimab (AB-122, GLS-010) a fully human, IgG4λ anti-programmed cell death protein-1 (PD-1) monoclonal antibody [1]. It is an immune checkpoint inhibitor class immuno-oncology therapeutic.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Lou B, Wei H, Yang F, Wang S, Yang B, Zheng Y, Zhu J, Yan S. (2021)
Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer.
Front Oncol, 11: 736955. [PMID:34604074]
2. Markham A. (2021)
Zimberelimab: First Approval.
Drugs, 81 (17): 2063-2068. [PMID:34709602]